![Robert Breedlove](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 493 896 $ in data 30/09/2026
Robert Breedlove is Chief Accounting Officer & Vice President-Finance at Phathom Pharmaceuticals, Inc. since 2025.
Former roles include Manager-Financial Reporting & Compliance at NeoGenomics, Inc. and Senior Manager at Van Den Boom & Associates LLC.
Education includes an undergraduate degree from the University of San Diego.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 03/09/2026 | 67.657 ( 0,08% ) | 493 896 $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 06/10/2025 |
| Società | Posizione | Fine |
|---|---|---|
| NEOGENOMICS, INC. | Responsabile della Conformità | - |
Van Den Boom & Associates LLC
 Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
NeoGenomics, Inc.
 NeoGenomics, Inc. Medical/Nursing ServicesHealth Services Provides genetic and molecular testing services | Health Services |
University of San Diego
 University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Van Den Boom & Associates LLC
Van Den Boom & Associates LLC Miscellaneous Commercial ServicesCommercial Services Provides accounting, financial, payroll, benefit and human resource services | Commercial Services |
Phathom Pharmaceuticals, Inc.
 Phathom Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel treatments for gastrointestinal diseases and disorders | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
